<DOC>
	<DOC>NCT01263353</DOC>
	<brief_summary>The purpose of this study is to assess the safety and tolerability of pasireotide LAR in combination with everolimus in advanced metastatic gastroenteropancreatic or pulmonary neuroendocrine Tumors (NET).</brief_summary>
	<brief_title>Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Confirmed diagnosis of grade 1/2 advanced pulmonary or gastroenteropancreatic neuroendocrine tumor Progressive disease within last 12 months (only patients with nonfunctional tumors) Documented liver metastasis Measurable disease per RECIST determined by multiphase MRI or triphasic CT Previous treatment with radiolabeled somatostatin analogs within 12 months prior to reporting baseline symptoms Previous treatment with mTOR inhibitors or pasireotide Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study Women who are pregnant or lactating Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Carcinoid tumor,</keyword>
	<keyword>Gastroenteropancreatic Neuroendocrine Tumors,</keyword>
	<keyword>Pulmonary Neuroendocrine Tumors,</keyword>
	<keyword>pasireotide LAR,</keyword>
	<keyword>SOM230 LAR,</keyword>
	<keyword>everolimus,</keyword>
	<keyword>RAD001,</keyword>
	<keyword>Advanced Neuroendocrine Tumor,</keyword>
	<keyword>Gastroenteropancreatic System</keyword>
</DOC>